CommercialAdministrativeLow impact
07.11.02f, Measurement of Exhaled Nitric Oxide and Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders
Independence Blue Cross·Pulmonology, Internal Medicine, Family Medicine +1 more·Medical Policy
We identified it
Jun 19, 2026
Summary
This is a routine annual reissue of Independence Blue Cross policy 07.11.02f with no substantive changes to coverage criteria. The policy maintains coverage for exhaled nitric oxide (CPT 95012) for asthma diagnosis and management (maximum 5 tests per 12 months) while continuing to classify exhaled breath condensate testing as experimental/investigational and non-covered.
Action Required
No immediate action required. This is a routine annual policy reissue with no changes to coverage status, billing codes, or medical necessity criteria. Billing team should verify that current system rules align with existing policy: CPT 95012 (exhaled nitric oxide) requires documentation of one of five covered asthma indications and is limited to 5 tests per 12-month period; CPT 83987 (exhaled breath condensate) should continue to be denied as experimental/investigational. No system updates or workflow changes are needed.